Personalized Atrial Fibrillation Ablation 2.0: AI-Driven, Real-Time Adaptive Therapy

This next-generation atrial fibrillation ablation technology leverages machine learning, real-time 3D imaging, and adaptive catheter design to provide a more effective, personalized, and minimally invasive treatment for patients.

The original patent's personalized atrial fibrillation ablation device, while innovative, has limitations in terms of its reliance on pre-procedure planning and fixed ablation patterns. This new inventive concept addresses these limitations by integrating AI-driven predictive analytics, real-time imaging, and adaptive catheter technology to create a more dynamic, responsive, and effective treatment approach.

The system comprises a machine learning module that analyzes a patient's 3D heart model to predict optimal ablation patterns, a catheter device configured to create the predicted ablation patterns in real-time, and a sensor array that monitors the effectiveness of the ablation treatment. The adaptive ablation panel adjusts its shape and size in real-time to conform to a patient's unique pulmonary vein anatomy, ensuring a more precise and effective treatment. The system also includes a real-time 3D imaging module that provides continuous guidance during the ablation procedure, enabling the navigation module to optimize catheter placement and reduce procedural time.

The new claims introduce the novel combination of machine learning, real-time imaging, and adaptive catheter technology, which enables a more dynamic, responsive, and effective treatment approach. This represents a significant departure from the original patent's fixed ablation patterns and pre-procedure planning, providing a more personalized and minimally invasive treatment for patients.

Alternative embodiments of the inventive concept could include the use of different machine learning algorithms, alternative imaging modalities, or variations in the adaptive catheter design. Additionally, the system could be integrated with other diagnostic tools, such as ECG or echocardiography, to further enhance its predictive capabilities.

This next-generation atrial fibrillation ablation technology has significant commercial potential in the electrophysiology and cardiology markets, with potential applications in hospitals, clinics, and research institutions. The market for atrial fibrillation ablation devices is expected to grow significantly in the coming years, driven by the increasing prevalence of atrial fibrillation and the need for more effective, minimally invasive treatment options.